These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20944079)

  • 1. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
    Freedman AN; Sansbury LB; Figg WD; Potosky AL; Weiss Smith SR; Khoury MJ; Nelson SA; Weinshilboum RM; Ratain MJ; McLeod HL; Epstein RS; Ginsburg GS; Schilsky RL; Liu G; Flockhart DA; Ulrich CM; Davis RL; Lesko LJ; Zineh I; Randhawa G; Ambrosone CB; Relling MV; Rothman N; Xie H; Spitz MR; Ballard-Barbash R; Doroshow JH; Minasian LM
    J Natl Cancer Inst; 2010 Nov; 102(22):1698-705. PubMed ID: 20944079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics and pharmacogenomics of anticancer agents.
    Huang RS; Ratain MJ
    CA Cancer J Clin; 2009; 59(1):42-55. PubMed ID: 19147868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
    Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
    Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conference scene: Latin American Pharmacogenomics and Personalized Medicine Conference.
    Suarez-Kurtz G
    Pharmacogenomics; 2012 Oct; 13(13):1449-52. PubMed ID: 23057544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics in cancer therapy: is host genome variability important?
    Petros WP; Evans WE
    Trends Pharmacol Sci; 2004 Sep; 25(9):457-64. PubMed ID: 15559247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics. Going from genome to pill.
    Service RF
    Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4th US FDA-Drug Information Association pharmacogenomics workshop, held 10-12 December, 2007.
    Frueh FW; Salerno RA; Lesko LJ; Hockett RD
    Pharmacogenomics; 2009 Jan; 10(1):111-5. PubMed ID: 19102720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Use of archived specimens in evaluation of prognostic and predictive biomarkers.
    Ahern TP; Hankinson SE
    J Natl Cancer Inst; 2011 Oct; 103(20):1558-9; author reply 1559-60. PubMed ID: 21917608
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
    Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
    Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
    Lesko LJ; Woodcock J
    Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
    Schuck RN; Grillo JA
    AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enabling pharmacogenomic clinical trials through sampling.
    Warner A; Nelsen A; Bhathena A; Fitzgerald K; Gilardi S; Kelso E; Knoppers B; McLeod HL; Nelson R; Uyama Y; Weisman J; Rudman A
    Pharmacogenomics; 2010 Dec; 11(12):1649-54. PubMed ID: 21142907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer pharmacogenomics: strategies and challenges.
    Wheeler HE; Maitland ML; Dolan ME; Cox NJ; Ratain MJ
    Nat Rev Genet; 2013 Jan; 14(1):23-34. PubMed ID: 23183705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.